Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general.
Makielski
Jonathan C
JC
Department of Medicine, Cardiovascular Medicine Section, University of Wisconsin, Madison, WI 53705, USA. jcm@medicine.wisc.edu
Valdivia
Carmen R
CR
D000083:Acetanilides / Q000494:pharmacology* / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy / Q000378:metabolism; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000378:metabolism; D008133:Long QT Syndrome / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D062554:NAV1.5 Voltage-Gated Sodium Channel; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D000069458:Ranolazine; D012964:Sodium / Q000378:metabolism; D026941:Sodium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D015222:Sodium Channels / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism
D000083:Acetanilides; D062554:NAV1.5 Voltage-Gated Sodium Channel; D010879:Piperazines; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D012964:Sodium; D000069458:Ranolazine